Health TrialsbyHealthPanel

Spontaneous Coronary Artery Dissection National Swiss Registry

ConditionSpontaneous Coronary Artery Dissection
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorDr. Sophie Degrauwe

About this trial

Spontaneous coronary artery dissection (SCAD), is an underdiagnosed pathology, affecting predominantly young women without traditional cardiovascular risk factors and is associated with major adverse outcomes including myocardial infarction, cardiac arrest, or death.

Timely diagnosis of SCAD as well as clinical follow-up are of the essence in this pathology associated with major cardiac adverse outcomes. Despite recent improvements in diagnosis and recognition of the importance of SCAD, it remains poorly studied and understood.

In this context, we designed the SwissSCAD registry, a large, observational, prospective, cohort study, to describe the natural history of SCAD, its outcomes and its treatments.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Subject is ≥18 years of age.

Patient presenting newly diagnosed SCAD or diagnosed with SCAD within the last 5 years.

Subject must be willing to sign a Patient Informed Consent (PIC).

Disqualifiers

Patient unwilling or unable to provide informed consent.

Patients with atherosclerotic or iatrogenic coronary dissection.

Trial population

This observational study will recruit consecutive male and female patients presenting with newly diagnosed SCAD or having been diagnosed with SCAD within the last 5 years. For the purposes of study inclusion, the definition of SCAD will be based on a central review of the coronary angiographic images confirmed by 2 independent assessors

Trial design

Design model

Cohort

Time perspective

Other

Treatments tested in this trial

Not listed

Trial groups

1,000 Participants
are grouped into 2 trial groups
Group A: Retrospective patients
Group B: Prospective patients

Trial outcomes

Primary outcomes

1

Incidence of safety events at 30 days

Incidence of Major cardiovascular outcomes (MACE) at 30 days

Time frame
30 days

Secondary outcomes

1

Incidence of safety events at 1 year

Incidence of Major cardiovascular outcomes (MACE) at 1 year

Time frame
1 year
2

Incidence of safety events at 5 years

Incidence of Major cardiovascular outcomes (MACE) at 5 years

Time frame
5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Dr. Sophie Degrauwe

Lead sponsor

University Hospital, Geneva

Sponsor institution

Source ClinicalTrials.gov
Apply now